3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Breast Neoplasms
20
Prostatic Neoplasms
7
Triple Negative Breast Neoplasms
6
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Melanoma
3
Lymphoma
3
Lung Neoplasms
3
Hematologic Neoplasms
3
Endometrial Neoplasms
3
Uterine Cervical Neoplasms
2
Recurrence
2
Neoplasms
2
Multiple Myeloma
2
Locally Advanced (Inoperable) or Metastatic Breast Cancer
2
Leukemia
2
Healthy Participants
2
Disease Progression
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumour
1
Rectal Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Interventions
adavosertib
5
durvalumab
3
Paclitaxel
3
olaparib
2
ceralasertib
2
Fluorouracil
2
Carboplatin
2
toripalimab
1
sintilimab
1
pembrolizumab
1
factor IX, factor VII, factor X, prothrombin drug combination
1
drug XX Z
1
danvatirsen
1
capivasertib
1
Rifampin
1
Pantoprazole
1
Omeprazole
1
Leucovorin
1
Itraconazole
1
Irinotecan
1
Injections
1
Gemcitabine
1
Doxorubicin
1
Cisplatin
1
AZD0156
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Advanced Solid Tumours
×
capivasertib
×
Clear all
NCT04742036
2022-08-19
Capivasertib China PK Study
AstraZeneca
Phase 1
Completed
16 enrolled